secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2026-01-09T23:59:59+00:00
Accession:  0001104659-26-002317
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

uniQure schedules Type A FDA meeting for accelerated approval of AMT-130 in Huntington's disease
--------------------------------------------------------------------------------

- Type A meeting with FDA scheduled to discuss BLA data package for accelerated approval of AMT-130 (Huntington's disease gene therapy).
- CEO Matt Kapusta emphasized commitment to constructive dialogue and timely resolution for patients with high unmet need.
- Regulatory update expected after receipt of official meeting minutes from the FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000110465926002317/0001104659-26-002317-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000110465926002317/qure-20260109x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-002317

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer